Cessatech (CESSA) Q2 2026 earnings summary

Executive summary

• Advanced paediatric pipeline with new CT004 program in collaboration with Rigshospitalet; Phase II study initiated and global rights retained.

• Achieved milestone with first commercial batch of CT001 released in the U.S., enabling launch activities with initial hospitals.

• European regulatory process for CT001 ongoing after negative CHMP opinion; re-examination process initiated with EMA.

• Maintains focus on capital efficiency and partner-driven commercialisation model.

Financial highlights

• Net revenue for Q2 2026 was DKK 0, compared to DKK 1,243,000 in Q2 2025.

• Operating result for Q2 2026 was DKK -3,469,000, nearly unchanged from DKK -3,554,000 in Q2 2025.

• Net loss for Q2 2026 was DKK -2,773,000, similar to DKK -2,785,000 in Q2 2025.

• Cash at bank at period end was DKK 2,348,000, down from DKK 15,051,000 at Q2 2025 end.

• Total equity as of 30 June 2026 was DKK 6,393,000.

Outlook and guidance

• Company expects minimal clinical and CMC costs for CT001 for the remainder of 2026 as development concludes.

• Loan facility of DKK 10,000,000 extended to 2027, supporting U.S. launch and providing financial flexibility.

• Cash position does not include the loan facility or expected tax return due in Q4 2026.